

Ashwin Ananthakrishnan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6910490/ashwin-ananthakrishnan-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

288
papers

17,130
citations

60
h-index

125
g-index

320
ext. papers

21,936
ext. citations

6.4
avg, IF

7.27
L-index

#	Paper	IF	Citations
288	Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases.. <i>Digestive Diseases and Sciences</i> , 2022 , 1	4	0
287	Inflammatory bowel diseases: pathogenesis 2022 , 1232-1247		
286	Robust and efficient semi-supervised estimation of average treatment effects with application to electronic health records data. <i>Biometrics</i> , 2021 , 77, 413-423	1.8	
285	Plasma concentrations of perfluoroalkyl substances and risk of inflammatory bowel diseases in women: A nested case control analysis in the Nurses' Health Study cohorts. <i>Environmental Research</i> , 2021 , 207, 112222	7.9	0
284	Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 598-607	6.1	0
283	Longitudinal Trajectory of Fatigue in Patients With Inflammatory Bowel Disease: A Prospective Study. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1740-1746	4.5	3
282	Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 3548-3554	4	2
281	Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1800-1813.e4	6.9	22
280	Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1366-1376.e2	6.9	22
279	Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2064-2071.e1	6.9	2
278	Nutrition in the Management of Inflammatory Bowel Diseases. <i>Gastroenterology Clinics of North America</i> , 2021 , 50, 151-167	4.4	2
277	Systematic Review of Inclusion and Analysis of Older Adults in Randomized Controlled Trials of Medications Used to Treat Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1541-1543	4.5	6
276	Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	3
275	Therapeutic Drug Monitoring of Non-Anti-Tumor Necrosis Factor Biologics. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1108-1110	6.9	1
274	High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	1
273	Plant-Based Diet Quality and Risk of Crohn's Disease and Ulcerative Colitis in US Women. <i>Current Developments in Nutrition</i> , 2021 , 5, 462-462	0.4	78
272	Healthy Lifestyle Is Associated With Reduced Mortality in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 87-95.e4	6.9	15

271	Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 519-527.e5	6.9	11
270	Phenotype and Natural History of Inflammatory Bowel Disease in Patients With Concomitant Eosinophilic Esophagitis. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 469-475	4.5	2
269	Characteristics and Long-Term Outcomes of Pregnancy-Onset Inflammatory Bowel Disease: A Case-Control Study. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 476-481	4.5	0
268	A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 760-767	4	4
267	Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn's Disease in Endoscopic Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1226-1233.e1	6.9	5
266	Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 939-946.e4	6.9	11
265	AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review. <i>Gastroenterology</i> , 2021 , 160, 445-451	13.3	5
264	Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 155-161	4.5	24
263	Yield of Random Biopsies During Colonoscopies in Inflammatory Bowel Disease Patients Undergoing Dysplasia Surveillance. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 779-786	4.5	7
262	Diet in Treatment of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 425-435.e3	6.9	25
261	Frailty in inflammatory bowel diseases: an emerging concept. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211025474	4.7	3
260	Economic burden and cost-effectiveness of therapies for infection: a narrative review. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211018654	4.7	6
259	Increasing Prevalence of Frailty and Its Association with Readmission and Mortality Among Hospitalized Patients with IBD. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 4178-4190	4	8
258	IBD risk prediction using multi-ethnic polygenic risk scores. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 217-218	24.2	0
257	Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 733-737	4	1
256	Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 590-592	4.5	
255	Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. <i>Cell Host and Microbe</i> , 2021 , 29, 1294-1304.e4	23.4	16
254	Ultra-processed Foods and Risk of Crohn's Disease and Ulcerative Colitis: A Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3

253	Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
252	The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 754-769	18.8	5
251	Efficacy and safety of fecal transplantation versus targeted therapies in ulcerative colitis: network meta-analysis. <i>Future Microbiology</i> , 2021 , 16, 1215-1227	2.9	0
250	Frailty in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2021 , 17, 263-268.	7	
249	Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 ,	6.1	3
248	Sugars and Gastrointestinal Health.. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
247	Dietary Inflammatory Potential and Risk of Crohn's Disease and Ulcerative Colitis. <i>Gastroenterology</i> , 2020 , 159, 873-883.e1	13.3	34
246	Clinical Research and Trials-A "Nonessential" Victim of the COVID-19 Pandemic?. <i>American Journal of Gastroenterology</i> , 2020 , 115, 946-947	0.7	2
245	Case 8-2020: An 89-Year-Old Man with Recurrent Abdominal Pain and Bloody Stools. <i>New England Journal of Medicine</i> , 2020 , 382, 1042-1052	59.2	0
244	Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2020 , 115, 340-349	0.7	19
243	Frailty is independently associated with mortality in 11001 patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 311-318	6.1	16
242	Assessment of Body Weight Changes in Patients with Inflammatory Bowel Diseases Initiating Biologic Therapy: A Prospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3672-3678	4	3
241	Pretreatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2020 , 158, 2104-2111.e2	13.3	40
240	Management of Inflammatory Bowel Diseases: Clinical Perspectives. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1249-1251	6.9	0
239	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1381-1392	6.9	71
238	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2500-2509.e1	6.9	8
237	Impact of Diet on Risk of IBD. <i>Crohn's & Colitis 360</i> , 2020 , 2,	1.4	3
236	Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1133-1141.e3	6.9	24

235	Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 347-355	6.1	23
234	Use of Narrative Concepts in Electronic Health Records to Validate Associations Between Genetic Factors and Response to Treatment of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1890-1892	6.9	2
233	Estimating average treatment effects with a double-index propensity score. <i>Biometrics</i> , 2020 , 76, 767-777.8		2
232	Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1926-1932	4.5	10
231	Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 872-880.e1	6.9	9
230	Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	5
229	Assessment of Benefit of Advanced Inflammatory Bowel Disease Training: Challenges and Solutions. <i>Crohn's & Colitis 360</i> , 2020 , 2, otaa019	1.4	0
228	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. <i>Crohn's & Colitis 360</i> , 2020 , 2, otaa039	1.4	1
227	Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1524-1532	4.5	11
226	Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1252-1260	6.9	65
225	Reply. <i>Gastroenterology</i> , 2020 , 159, 1993-1994		13.3
224	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1760-1768.e1	6.9	7
223	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 14-23	6.9	38
222	Interval Colorectal Cancer in Inflammatory Bowel Disease: The Role of Guideline Adherence. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 111-118	4	4
221	Gastrointestinal Diseases 2020 , 16-26		2
220	Association Between Vulvovaginal Discomfort and Activity of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 604-611.e1	6.9	7
219	Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 309-315	1.5	13
218	Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. <i>Advances in Therapy</i> , 2019 , 36, 3079-3095	4.1	9

217	The Crohn's disease polymorphism, T300A, alters the gut microbiota and enhances the local Th1/Th17 response. <i>ELife</i> , 2019 , 8,	8.9	50
216	Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Crohn's & Colitis</i> 360 , 2019 , 1, otz009	1.4	6
215	Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. <i>Nature</i> , 2019 , 569, 655-662	50.4	761
214	Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 990-995	1.5	4
213	Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1736-1743.e4	6.9	43
212	Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 773-783	27.4	75
211	CT-Visualized Colonic Mural Stratification Independently Predicts the Need for Medical or Surgical Rescue Therapy in Hospitalized Ulcerative Colitis Patients. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 2265-2272 ¹	4	2272 ¹
210	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1919	6.9	
209	Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. <i>Cell</i> , 2019 , 178, 714-730.e32	32	359
208	The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019 , 29, 447-470	3.3	20
207	Influence of Environmental Factors in the Development and Outcomes of Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2019 , 15, 72-82	0.7	14
206	Comparative safety and effectiveness of tumor necrosis factor antagonists and vedolizumab in elderly IBD patients: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 873-879	6.1	44
205	High-throughput phenotyping with electronic medical record data using a common semi-supervised approach (PheCAP). <i>Nature Protocols</i> , 2019 , 14, 3426-3444	18.8	41
204	ACG Clinical Guideline: Ulcerative Colitis in Adults. <i>American Journal of Gastroenterology</i> , 2019 , 114, 384-413	473	458
203	Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 502-509.e1	6.9	39
202	Patient age determines adherence to preventive care measures among patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2019 , 51, 178-179	3.3	
201	Comparable perioperative outcomes, long-term outcomes, and quality of life in a retrospective analysis of ulcerative colitis patients following 2-stage versus 3-stage proctocolectomy with ileal pouch-anal anastomosis. <i>International Journal of Colorectal Disease</i> , 2019 , 34, 491-499	3	15
200	Cancer risk in microscopic colitis: a retrospective cohort study. <i>BMC Gastroenterology</i> , 2019 , 19, 1	3	30

199	Fatigue in IBD: epidemiology, pathophysiology and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 247-259	24.2	68
198	The Gut Microbiome and Digestive Health - A New Frontier. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 215-217	6.9	2
197	Paternal Disease Activity Is Associated With Difficulty in Conception Among Men With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 203-204	6.9	3
196	Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 559-567	1.5	22
195	Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 738-745	4	11
194	Enabling phenotypic big data with PheNorm. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018 , 25, 54-60	8.6	48
193	Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. <i>Nature Microbiology</i> , 2018 , 3, 337-346	26.6	249
192	Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 525-531	1.5	16
191	Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1840-1848	4.5	29
190	Effect of oral tobacco use and smoking on outcomes of Crohn's disease in India. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 134-140	4	8
189	Ethnicity Influences Phenotype and Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 190-197.e11	6.9	47
188	Environmental triggers in IBD: a review of progress and evidence. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 39-49	24.2	290
187	Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 99-105	6.9	63
186	Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 2740-2746	4	8
185	Reply to 'Comment on Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients'. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1256	1.5	10
184	Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1036-1041	1.5	10
183	Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort. <i>Scientific Reports</i> , 2018 , 8, 12699	4.9	27
182	A low-cost paper-based synthetic biology platform for analyzing gut microbiota and host biomarkers. <i>Nature Communications</i> , 2018 , 9, 3347	17.4	139

181	Asians have more perianal Crohn disease and ocular manifestations compared with white Americans. <i>Inflammatory Intestinal Diseases</i> , 2018 , 2, 147-153	2.5	7
180	A Case Study of the Incremental Utility for Disease Identification of Natural Language Processing in Electronic Medical Records. <i>Pharmaceutical Medicine</i> , 2018 , 32, 31-37	2.3	4
179	"Weekend Effect" in Patients With Upper Gastrointestinal Hemorrhage: A Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2018 , 113, 13-21	0.7	18
178	Identification of Menopausal and Reproductive Risk Factors for Microscopic Colitis-Results From the Nurses' Health Study. <i>Gastroenterology</i> , 2018 , 155, 1764-1775.e2	13.3	17
177	Bugs and drugs: Predicting response to therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33 Suppl 3, 27	4	
176	The Effect of Early-Life Environmental Exposures on Disease Phenotype and Clinical Course of Crohn's Disease in Children. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1524-1529	0.7	21
175	Making sense of clinical predictors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33 Suppl 3, 7-8	4	
174	Debate session: So what causes inflammatory bowel disease? It's all in the environment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33 Suppl 3, 24	4	3
173	The role of diet in the aetiopathogenesis of inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 525-535	24.2	92
172	Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2634-2640	4.5	8
171	IRGM Gene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2247-2257	4.5	8
170	Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis?. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 2445-2450	4	8
169	The Association Between Arthralgia and Vedolizumab Using Natural Language Processing. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2242-2246	4.5	15
168	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1177	6.9	
167	Development of a Sexual Dysfunction Scale for Women With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2350-2359	4.5	9
166	The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 814-823	6.1	16
165	Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 269-276	18.8	83
164	Genetic risk factors for serious infections in inflammatory bowel diseases. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 570-576	2.4	5

163	Modifiable Environmental Factors in Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2017 , 19, 21	5	22
162	Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 882-893	4.5	44
161	Inflammatory Bowel Disease is Similar in Patients with Older Onset and Younger Onset. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1187-1194	4.5	12
160	Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. <i>Cell Host and Microbe</i> , 2017 , 21, 603-610.e3	23.4	187
159	The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 162-168	6.1	13
158	Dietary Iron and Heme Iron Consumption, Genetic Susceptibility, and Risk of Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1088-1095	4.5	15
157	Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1291-1302	6.1	160
156	Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 1590-1596	4	47
155	Epidemiology and Pathogenesis 2017 , 1-15		
154	Medical Management of Ulcerative Colitis 2017 , 131-147		
153	Medical Management of Crohn's Disease 2017 , 149-157		
152	Surgical Management of Inflammatory Bowel Diseases 2017 , 159-170		
151	Complications of Inflammatory Bowel Diseases 2017 , 171-187		
150	Nutrition in Inflammatory Bowel Diseases 2017 , 189-197		
149	Pregnancy, Conception, and Childbirth 2017 , 199-207		
148	Inflammatory Bowel Disease During Childhood and Adolescence 2017 , 209-216		
147	Clinical Features and Diagnosis of Crohn's Disease 2017 , 17-31		
146	Clinical Features and Diagnosis of Ulcerative Colitis 2017 , 33-47		1

145 Extraintestinal Manifestations of Inflammatory Bowel Diseases **2017**, 49-61

144 Aminosalicylates **2017**, 63-73

143 Immunomodulators **2017**, 85-99

142 Biologic Therapies **2017**, 101-121

141 A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection. *Infection Control and Hospital Epidemiology*, **2017**, 38, 196-202 2 30

140 Filgotinib for Crohn's disease-expanding treatment options. *Lancet, The*, **2017**, 389, 228-229 40 4

139 Genetic Polymorphisms in Fatty Acid Metabolism Modify the Association Between Dietary n3: n6 Intake and Risk of Ulcerative Colitis: A Prospective Cohort Study. *Inflammatory Bowel Diseases*, **2017**, 23, 1898-1904 4.5 18

138 Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease-Authors' reply. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 1026-1027 6.1

137 Pivot to Asia: inflammatory bowel disease burden. *Intestinal Research*, **2017**, 15, 138-141 4.1 48

136 The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact. *PLoS ONE*, **2017**, 12, e0176797 3.7 55

135 Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 780-789 6.1 78

134 Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 645-656 6.1 77

133 Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease-Authors' reply. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 1121 6.1

132 Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. *Digestive Diseases and Sciences*, **2017**, 62, 197-206 4 34

131 Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 3-13 6.1 127

130 Surrogate-assisted feature extraction for high-throughput phenotyping. *Journal of the American Medical Informatics Association: JAMIA*, **2017**, 24, e143-e149 8.6 37

129 **2017**, 2

128 Infliximab or ciclosporin for acute severe ulcerative colitis?. *The Lancet Gastroenterology and Hepatology*, **2016**, 1, 2-3 18.8 0

127	A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. <i>Nature Communications</i> , 2016 , 7, 12342	17.4	41
126	Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 880-5	4.5	29
125	Metagenomic Characterization of Microbial Communities Within the Deeper Layers of the Ileum in Crohn's Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016 , 2, 563-566.e5	7.9	16
124	Discontinuity of care for mothers with chronic hepatitis B diagnosed during pregnancy. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 561-8	3.4	9
123	Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 818-824.e6	6.9	37
122	Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 973-9	6.9	46
121	Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 1224-36	1.5	78
120	Computer-assisted expert case definition in electronic health records. <i>International Journal of Medical Informatics</i> , 2016 , 86, 62-70	5.3	25
119	Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding. <i>American Journal of Medicine</i> , 2016 , 129, 628-34	2.4	7
118	Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 58-64	6.9	65
117	Identification and Characterization of a Novel Association between Dietary Potassium and Risk of Crohn's Disease and Ulcerative Colitis. <i>Frontiers in Immunology</i> , 2016 , 7, 554	8.4	28
116	HBV/HIV coinfection is associated with poorer outcomes in hospitalized patients with HBV or HIV. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 820-9	3.4	28
115	Clostridium difficile associated risk of death score (CARDS): a novel severity score to predict mortality among hospitalised patients with C. difficile infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 725-33	6.1	46
114	Identification of Nonresponse to Treatment Using Narrative Data in an Electronic Health Record Inflammatory Bowel Disease Cohort. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 151-8	4.5	14
113	Environmental Hygiene and Risk of Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 2191-9	4.5	42
112	Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2016 , 151, 97-109.e4	13.3	83
111	Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 2627-35	4	12
110	P-014 Circulating C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, S13-S14	4.5	

109	Racial Disparities in Inhospital Outcomes for Hepatocellular Carcinoma in the United States. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1173-82	6.4	11
108	A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. <i>Gastroenterology</i> , 2016 , 151, 724-32	13.3	77
107	Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 52-60	6.1	17
106	Epidemiology and risk factors for IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 205-17	14.2	783
105	High C-Reactive Protein Is Associated with Poor Sleep Quality Independent of Nocturnal Symptoms in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 2136-43	4	38
104	Mode of childbirth and long-term outcomes in women with inflammatory bowel diseases. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 471-7	4	19
103	Patient Electronic Health Records as a Means to Approach Genetic Research in Gastroenterology. <i>Gastroenterology</i> , 2015 , 149, 1134-7	13.3	3
102	Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1197-200	6.9	38
101	Measures of obesity and risk of Crohn's disease and ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 361-8	4.5	87
100	Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 1141-8	6.1	27
99	Environmental risk factors for inflammatory bowel diseases: a review. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 290-8	4	99
98	Inflammatory Bowel Diseases: Pathogenesis 2015 , 1364-1377		1
97	High School Diet and Risk of Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2311-9	4.5	59
96	New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 972-9	6.1	41
95	Development of phenotype algorithms using electronic medical records and incorporating natural language processing. <i>BMJ, The</i> , 2015 , 350, h1885	5.9	159
94	Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2304-2310	4.5	29
93	Common Genetic Variants Influence Circulating Vitamin D Levels in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2507-14	4.5	23
92	Zinc intake and risk of Crohn's disease and ulcerative colitis: a prospective cohort study. <i>International Journal of Epidemiology</i> , 2015 , 44, 1995-2005	7.8	51

91	Reply: To PMID 25041865. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1703-4	6.9	
90	Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 322-329.e1	6.9	80
89	Surgery for Crohn's disease: look harder, act faster. <i>Lancet, The</i> , 2015 , 385, 1370-1	40	7
88	Methods to Develop an Electronic Medical Record Phenotype Algorithm to Compare the Risk of Coronary Artery Disease across 3 Chronic Disease Cohorts. <i>PLoS ONE</i> , 2015 , 10, e0136651	3.7	57
87	Cost-effectiveness of competing strategies for management of recurrent <i>Clostridium difficile</i> infection: a decision analysis. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1507-14	11.6	107
86	Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 821-7	6.9	82
85	Differential effect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis: analysis of a North American cohort. <i>American Journal of Gastroenterology</i> , 2014 , 109, 395-400	0.7	67
84	Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. <i>Gut</i> , 2014 , 63, 776-84	19.2	259
83	Review article: vitamin D and inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 125-36	6.1	142
82	Sleep duration affects risk for ulcerative colitis: a prospective cohort study. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1879-86	6.9	51
81	Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1342-8.e1	6.9	33
80	Reply: To PMID 24703865. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1577-8	6.9	
79	SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 845-51	1.5	36
78	Early life environment and natural history of inflammatory bowel diseases. <i>BMC Gastroenterology</i> , 2014 , 14, 216	3	24
77	Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor- α therapy in inflammatory bowel diseases. <i>Journal of Parenteral and Enteral Nutrition</i> , 2014 , 38, 385-91	4.2	80
76	Evaluation of matched control algorithms in EHR-based phenotyping studies: a case study of inflammatory bowel disease comorbidities. <i>Journal of Biomedical Informatics</i> , 2014 , 52, 105-11	10.2	14
75	Higher plasma vitamin D is associated with reduced risk of <i>Clostridium difficile</i> infection in patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1136-42	6.1	44
74	Vitamin D deficiency is associated with community-acquired <i>clostridium difficile</i> infection: a case-control study. <i>BMC Infectious Diseases</i> , 2014 , 14, 661	4	10

73	Genetic polymorphisms in metabolizing enzymes modifying the association between smoking and inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 783-9	4.5	26
72	Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1905-10	6.9	45
71	Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 956-63	1.5	40
70	Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 37-44	4.5	35
69	Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 309-15	4.5	96
68	Treatment of intra-abdominal abscesses in Crohn's disease: a nationwide analysis of patterns and outcomes of care. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 2013-8	4	20
67	Interobserver agreement for the detection of Barrett's esophagus with optical frequency domain imaging. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 2261-5	4	37
66	Dyssynergic defecation: a treatable cause of persistent symptoms when inflammatory bowel disease is in remission. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 3600-5	4	24
65	A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. <i>Gastroenterology</i> , 2013 , 145, 970-7	13.3	337
64	Personalizing therapy for inflammatory bowel diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013 , 7, 549-58	4.2	7
63	Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 965-71	6.9	139
62	Association between depressive symptoms and incidence of Crohn's disease and ulcerative colitis: results from the Nurses' Health Study. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 57-62	6.9	92
61	Antibiotic exposure is associated with development of inflammatory bowel disease. <i>Journal of Pediatrics</i> , 2013 , 162, 1077	3.6	1
60	Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 445-54	6.1	74
59	Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1123-9	0.7	40
58	Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. <i>American Journal of Gastroenterology</i> , 2013 , 108, 478-98; quiz 499	0.7	1147
57	Similar risk of depression and anxiety following surgery or hospitalization for Crohn's disease and ulcerative colitis. <i>American Journal of Gastroenterology</i> , 2013 , 108, 594-601	0.7	54
56	Environmental triggers for inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , 2013 , 15, 302	5	79

55	Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, 107-12	1.5	114
54	Improving case definition of Crohn's disease and ulcerative colitis in electronic medical records using natural language processing: a novel informatics approach. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 1411-20	4.5	107
53	Genetic risk factors for Clostridium difficile infection in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 522-30	6.1	42
52	Weekend hospitalisations and post-operative complications following urgent surgery for ulcerative colitis and Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 895-904	6.1	31
51	Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 1921-7	4.5	152
50	Early life factors and risk of inflammatory bowel disease in adulthood. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 542-7	4.5	32
49	P-056 Aryl Hydrocarbon Receptor Expression: A Comparison Between Patients with IBD and Healthy Controls, and Association with Serum Fatty Acids. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, S49-S50 ⁴⁵		
48	How does genotype influence disease phenotype in inflammatory bowel disease?. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 2021-30	4.5	12
47	Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 459-66	6.1	41
46	Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. <i>Digestive Diseases and Sciences</i> , 2012 , 57, 472-80	4	17
45	Impact of pregnancy on health-related quality of life of patients with inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2012 , 13, 472-7	3.3	6
44	Geographical variation and incidence of inflammatory bowel disease among US women. <i>Gut</i> , 2012 , 61, 1686-92	19.2	150
43	Detecting and treating Clostridium difficile infections in patients with inflammatory bowel disease. <i>Gastroenterology Clinics of North America</i> , 2012 , 41, 339-53	4.4	27
42	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. <i>Nature</i> , 2012 , 491, 119-24	50.4	3239
41	Reply to Dr. McNabb-Baltar's letter. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 868	1.5	
40	Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 789-95	6.1	63
39	Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. <i>Annals of Internal Medicine</i> , 2012 , 156, 350-9	8	162
38	Clostridium difficile infection: epidemiology, risk factors and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 8, 17-26	24.2	273

37	Geographic variation and the incidence of inflammatory bowel disease among U.S. women. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, S15	4.5	
36	Fracture-associated hospitalizations in patients with inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 176-82	4	16
35	Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 2152-9	4	61
34	A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. <i>Journal of Gastrointestinal Surgery</i> , 2011 , 15, 267-76	3.3	53
33	Physician density and hospitalization for inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 633-8	4.5	6
32	Ambient air pollution correlates with hospitalizations for inflammatory bowel disease: an ecologic analysis. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 1138-45	4.5	99
31	Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 976-83	4.5	117
30	Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 2009-17	0.7	41
29	Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with hepatitis C or HIV. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 720-9	3.4	17
28	Trends in ambulatory and emergency room visits for inflammatory bowel diseases in the United States: 1994-2005. <i>American Journal of Gastroenterology</i> , 2010 , 105, 363-70	0.7	45
27	A novel risk score to stratify severity of Crohn's disease hospitalizations. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1799-807	0.7	37
26	Length of office visits for gastrointestinal disease: impact of physician specialty. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1719-25	0.7	6
25	Clostridium difficile and inflammatory bowel disease. <i>Medical Clinics of North America</i> , 2010 , 94, 135-53	7	32
24	Impact of Clostridium difficile on inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010 , 4, 589-600	4.2	24
23	Impact of autonomic dysfunction on inflammatory bowel disease. <i>Journal of Clinical Gastroenterology</i> , 2010 , 44, 272-9	3	21
22	Laparoscopic resection for inflammatory bowel disease: outcomes from a nationwide sample. <i>Journal of Gastrointestinal Surgery</i> , 2010 , 14, 58-65	3.3	20
21	Higher physician density is associated with lower incidence of late-stage colorectal cancer. <i>Journal of General Internal Medicine</i> , 2010 , 25, 1164-71	4	49
20	Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease?. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 494-500	4.5	17

19	Clostridium difficile and inflammatory bowel disease: more questions than answers?. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1445-6	4.5	4
18	Simple score to identify colectomy risk in ulcerative colitis hospitalizations. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1532-40	4.5	31
17	Treatment of ulcerative colitis in the elderly. <i>Digestive Diseases</i> , 2009 , 27, 327-34	3.2	31
16	Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 182-9	4.5	142
15	History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 176-81	4.5	57
14	Higher hospital volume predicts endoscopy but not the in-hospital mortality rate in patients with acute variceal hemorrhage. <i>Gastrointestinal Endoscopy</i> , 2009 , 69, 221-9	5.2	9
13	Higher hospital volume is associated with lower mortality in acute nonvariceal upper-GI hemorrhage. <i>Gastrointestinal Endoscopy</i> , 2009 , 70, 422-32	5.2	20
12	Outcomes of weekend admissions for upper gastrointestinal hemorrhage: a nationwide analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 296-302e1	6.9	125
11	Clostridium difficile and inflammatory bowel disease. <i>Gastroenterology Clinics of North America</i> , 2009 , 38, 711-28	4.4	44
10	Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. <i>Gut</i> , 2008 , 57, 205-10	19.2	305
9	Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2789-98	0.7	96
8	Permanent work disability in Crohn's disease. <i>American Journal of Gastroenterology</i> , 2008 , 103, 154-61	0.7	83
7	Racial differences in liver transplantation outcomes in the MELD era. <i>American Journal of Gastroenterology</i> , 2008 , 103, 901-10	0.7	60
6	Effect of hospital volume and teaching status on outcomes of acute liver failure. <i>Liver Transplantation</i> , 2008 , 14, 1347-56	4.5	23
5	Disparities in colon cancer screening in the Medicare population. <i>Archives of Internal Medicine</i> , 2007 , 167, 258-64		97
4	Caroli's disease: identification and treatment strategy. <i>Current Gastroenterology Reports</i> , 2007 , 9, 151-5	5	37
3	Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. <i>Journal of Clinical Gastroenterology</i> , 2007 , 41, 682-8	3	44
2	Epidemiology of primary and secondary liver cancers. <i>Seminars in Interventional Radiology</i> , 2006 , 23, 47-63	6	122

1 Clostridium Difficile in IBD: Impact, Prevention, and Treatment30-33